Alnylam Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 02/04/2023
Alnylam Pharmaceuticals Stock Forecast and Price Target
In recent months, seven notable analysts have provided yearlong price targets for Alnylam Pharmaceuticals, with the average target coming in at $251.00. If it were to be achieved, this would result in a potential upside of approximately 7.55 percent from the most recent closing price in February, 2023. The high end is $415.00, and the low is $143.00. Although you may not be interested in ALNY stock, you should still be aware of its competitors.
7.55% Upside
Alnylam Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Alnylam Pharmaceuticals's Price has grown from $0.00 to $0.00 – a 100.00% increase. Next year, analysts are expecting Fair Value to reach $256.84 – an increase of 100.00%. Over the next eight years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$339.08 | $333.19 | 17.97% |
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
10
|
kr967.50 | kr937.82 | 0.78% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$44.06 | $53.97 | 19.50% |
| AMGN Stock Forecast | Amgen Inc | Hold |
7
|
$245.17 | $268.00 | 13.39% |
| SAN Stock Forecast | Sanofi | Outperform |
10
|
91.12€ | 108.44€ | 20.72% |
Alnylam Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Alnylam Pharmaceuticals's Revenue has grown from $219.75M to $844.29M – a 284.20% increase. Next year, analysts are expecting Revenue to reach $1.47B – an increase of 73.79%. Over the next eight years, the forecast is for Revenue to grow by 1046.69%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| MRNA Stock Forecast | Moderna | Outperform |
11
|
$173.25 | $0.00 | 23.23% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.07k | ¥0.00 | 35.30% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
56.68€ | 74.54€ | 33.20% |
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$112.20 | $115.45 | 6.95% |
| SRPT Stock Forecast | Sarepta Therapeutics | Outperform |
6
|
$119.00 | $139.65 | 27.73% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$40.92 | $52.42 | 22.19% |
Alnylam Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Alnylam Pharmaceuticals's Free Cash Flow has grown, rising from $-418.59M to $-712.05M – a growth of 70.11%. In the following year, the 8 analysts surveyed believe that Alnylam Pharmaceuticals's Free Cash Flow will decrease by 41.00%, reaching $-420.13M. According to professionals, by 2030, Alnylam Pharmaceuticals's Free Cash Flow will have decreased by 577.28%, falling down to $3.40B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| 4516 Stock Forecast | Nippon Shinyaku | Outperform |
18
|
¥7.07k | ¥0.00 | 55.59% |
| DCPH Stock Forecast | Deciphera Pharmaceuticals | Hold |
6
|
$17.03 | $0.00 | -41.28% |
| STOK Stock Forecast | Stoke Therapeutics | Buy |
4
|
$9.44 | $61.44 | 450.85% |
Alnylam Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Alnylam Pharmaceuticals's Net Income has decreased from $-886.12M to $-852.82M – a 3.76% drop. For the following year, the 12 analysts predict that Alnylam Pharmaceuticals's Net Income will drop by 37.69%, reaching $-531.38M. In 2030, the professionals' prediction is that ALNY's Net Income will decrease by 587.77%, reaching $4.16B.
Alnylam Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Alnylam Pharmaceuticals's EBITDA has decreased from $-922.26M to $-661.09M – a 28.32% drop! The next year, 8 experts forecast that Alnylam Pharmaceuticals's EBITDA will decrease by 15.04%, reaching $-561.69M. In 2030, professionals predict that Alnylam Pharmaceuticals's EBITDA will decrease by 400.28%, reaching $1.99B.
Alnylam Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Alnylam Pharmaceuticals has seen a decline in its EBIT, from $-939.43M to $-708.65M – a 24.57% decrease. In the next year, analysts believe that EBIT will reach $-745.30M – an increase of 5.17%. By 2030, professionals believe that Alnylam Pharmaceuticals's EBIT will have decreased by 866.53%, falling to $5.43B.
Alnylam Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Alnylam Pharmaceuticals's EPS has decreased from $-6.70 to $-6.14 – a 8.36% drop. Next year, analysts are expecting EPS to reach $-6.56 – an increase of 6.84%. In 2030, professionals predict that Alnylam Pharmaceuticals's EPS will decrease by 540.72%, to $27.06.